Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZYNRELEF KIT vs EXPAREL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Zynrelef is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction. Meloxicam inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and inflammation.
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, inhibiting nerve impulse conduction and providing prolonged analgesia.
Zynrelef is indicated for the production of local analgesia for surgical wounds in adults for up to 72 hours after surgery.
Single-dose infiltration for postsurgical analgesia in adults,Interscalene brachial plexus nerve block for postsurgical analgesia in adults
Instillation into the surgical site: 20 m L (300 mg bupivacaine and 9.3 mg meloxicam) as a single dose.
Local infiltration: up to 266 mg (20 m L) as a single dose; interscalene brachial plexus block: up to 133 mg (10 m L); femoral nerve block: up to 133 mg (10 m L). Maximum dose 266 mg. Administer via slow injection with frequent aspiration.
Terminal half-life of bupivacaine (component) is 3.5 hours; for meloxicam (component) is 20 hours. Clinical context: bupivacaine half-life prolonged in hepatic impairment; meloxicam half-life prolonged in elderly (up to 25 hours)
Terminal elimination half-life is 12-48 hours (mean ~24 hours), reflecting prolonged release from the multivesicular liposome depot.
Bupivacaine is primarily metabolized by the liver via conjugation with glucuronic acid; the major metabolite is pipecoloxylidine. Meloxicam is extensively metabolized in the liver by CYP2C9 (major) and CYP3A4 (minor) to four inactive metabolites.
Avoid use in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²). No dose adjustment recommended for mild to moderate impairment (e GFR 30-89 m L/min/1.73 m²).
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
WARNING: CARDIOVASCULAR RISK WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs); AND WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS. NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Zynrelef is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk.
ZYNRELEF (bupivacaine and meloxicam) is a local anesthetic and NSAID combination. For bupivacaine, not teratogenic in animals; limited human data. For meloxicam, NSAIDs are associated with premature closure of the ductus arteriosus starting at 30 weeks gestation, oligohydramnios, and increased risk of miscarriage. First trimester: potential risk of miscarriage and malformations (meloxicam). Second trimester: avoid prolonged use due to oligohydramnios risk. Third trimester: contraindicated after 30 weeks due to fetal ductus arteriosus constriction.
EXPAREL (liposomal bupivacaine) has not been studied in pregnant women. Animal reproduction studies have not been conducted with EXPAREL. Bupivacaine HCl, the active moiety, crosses the placenta. In pregnant women, bupivacaine can cause fetal bradycardia and neonatal depression when used for labor analgesia. Use during first trimester: Limited data; risk cannot be excluded. Use during second trimester: Consider risk-benefit. Use during third trimester: Avoid high doses near term due to potential fetal and neonatal adverse effects.
ZYNRELEF (bupivacaine and meloxicam) is an NSAID-containing local anesthetic; avoid concomitant use with other NSAIDs, anticoagulants, or drugs affecting renal function. Monitor for signs of neuraxial toxicity if used near the spine. Not for intravenous or epidural administration. Do not use in patients with known NSAID hypersensitivity, renal impairment, or active peptic ulcer disease.
Exparel (liposomal bupivacaine) is a long-acting local anesthetic formulation. It should not be used in place of traditional local anesthetics for immediate postoperative pain control; a short-acting agent may be co-administered. Avoid concurrent use with other local anesthetics as it may alter liposomal release. Do not use with non-bupivacaine local anesthetics. Exparel is contraindicated in patients with hypersensitivity to bupivacaine or amide anesthetics. Do not administer intravascularly; monitor for CNS and cardiac toxicity. Use with caution in hepatic impairment. Maximum dose is 266 mg (20 m L of 1.3% solution) in adults.
No interactions on record
No interactions on record
ZYNRELEF KIT and EXPAREL are distinct pharmacological agents. ZYNRELEF KIT belongs to the Local Anesthetic and NSAID Combination class and is primarily used for Zynrelef is indicated for the production of local analgesia for surgical wounds in adults for up to 72 hours after surgery.. EXPAREL belongs to the Local Anesthetic class and is primarily used for Single-dose infiltration for postsurgical analgesia in adultsInterscalene brachial plexus nerve block for postsurgical analgesia in adults. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. ZYNRELEF KIT carries a safety status of Category C, whereas EXPAREL safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hepatic metabolism primarily via conjugation with glucuronic acid; minor metabolism by CYP450 enzymes (CYP3A4, CYP1A2, CYP2D6).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal (approximately 96% as metabolites, <10% unchanged). Biliary/fecal excretion is negligible.
Bupivacaine: 95% bound to alpha-1-acid glycoprotein; meloxicam: 99% bound to albumin
Approximately 96% bound to alpha-1-acid glycoprotein (AAG) and albumin, with binding dependent on drug concentration and AAG levels.
Bupivacaine: Vd 1.0 L/kg (extensive tissue distribution); meloxicam: Vd 0.15 L/kg (confined to plasma)
After IV administration of free bupivacaine: ~0.6-0.8 L/kg. For Exparel, Vd is not directly applicable due to local administration; systemic Vd reflects released bupivacaine.
Local infiltration: 100% (site of action); not administered systemically
Not applicable for IV route; after local infiltration, systemic bioavailability is essentially 100% due to complete absorption from the depot over time.
Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment recommended for mild to moderate impairment (Child-Pugh Class A or B).
No dosage adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe impairment (Child-Pugh B or C); use with caution due to potential for increased systemic exposure.
Not approved for pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients <18 years of age due to lack of safety and efficacy data.
No specific dose adjustment required, but elderly patients may be more sensitive to systemic effects; use caution with concomitant NSAIDs or anticoagulants.
No specific dosage adjustment required. Monitor for prolonged duration of sensory and motor block; consider reduced doses based on clinical status (e.g., frailty, comorbidities).
None.
Cardiovascular thrombotic events; Gastrointestinal bleeding, ulceration, and perforation; Hepatotoxicity; Hypertension; Heart failure and edema; Renal toxicity; Anaphylactic reactions; Serious skin reactions; Hematologic toxicity; Central nervous system effects (e.g., convulsions, cardiac arrest) with bupivacaine; Risk of chondrolysis with intra-articular use; Risk of nerve damage with regional block; Risk of methemoglobinemia; Use in patients with known or suspected sulfite sensitivity.
Hypersensitivity to bupivacaine, meloxicam, or any component of the product; History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; In the setting of CABG surgery; Patients with severe hepatic impairment; Patients with severe renal impairment (e GFR <15 m L/min/1.73 m²); Patients with a history of gastrointestinal bleeding or perforation related to previous NSAID therapy; Active peptic ulcer disease; Patients with a history of hypersensitivity to local anesthetics of the amide type.
No specific food interactions; avoid alcohol consumption as it may increase the risk of gastrointestinal bleeding and renal impairment.
No known food interactions. Avoid alcohol consumption as it may increase the risk of central nervous system depression.
Bupivacaine: excreted in breast milk in small amounts; infant dose <0.1% of maternal dose. M/P ratio: bupivacaine ~0.25. Meloxicam: excreted in breast milk; M/P ratio 0.19-0.36. Relative infant dose ~1.8% of weight-adjusted maternal dose. Use with caution; discontinue breastfeeding if infant shows signs of NSAID toxicity.
Bupivacaine is excreted in human milk in small amounts. The milk-to-plasma (M/P) ratio for bupivacaine is approximately 0.3 to 0.5. After epidural administration, the relative infant dose is estimated to be <4% of the maternal weight-adjusted dose. EXPAREL has not been studied in lactating women. Clinical implications: Caution is advised; monitor the infant for signs of local anesthetic toxicity (e.g., irritability, feeding difficulties).
No specific dose adjustment is recommended for pregnancy. However, due to altered pharmacokinetics in pregnancy (increased volume of distribution, decreased protein binding), consider dose reduction for meloxicam component to avoid NSAID toxicity. Maximal single dose of bupivacaine should not exceed 2 mg/kg. Avoid use after 30 weeks gestation.
Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, decreased plasma protein binding) may alter bupivacaine disposition. However, specific dose adjustment guidelines for EXPAREL in pregnancy are not established. The dose should be individualized based on the surgical site, patient weight, and clinical condition. Avoid exceeding the maximum recommended dose (266 mg for single-dose administration). Use with caution in severe preeclampsia or hepatic impairment due to altered clearance.
ZYNRELEF is a single-dose medication given during surgery for pain relief lasting up to 72 hours.,Do not take additional NSAIDs (e.g., ibuprofen, naproxen) while this drug is active without consulting your doctor.,Seek immediate medical attention if you experience signs of infection, bleeding, or allergic reaction at the surgical site.,Inform your healthcare provider about all medications you take, especially blood thinners, aspirin, or other pain relievers.,This drug may impair kidney function; stay hydrated and report decreased urination or swelling.
Exparel is a long-acting numbing medicine that provides pain relief for up to 72 hours after surgery.,It is injected into the surgical site by your doctor before or during surgery.,You may still feel some sensation, but pain should be significantly reduced.,Do not apply heat or cold packs directly over the injection area for 24 hours.,Avoid strenuous activity or heavy lifting until your doctor advises it is safe.,Seek medical help if you experience symptoms like severe headache, confusion, ringing in ears, vision changes, or metallic taste.